Special Session
COVID-19 and Treatment of Moderate to Severe Atopic Dermatitis: The Role of Systemic Agents
The International Eczema Council (IEC) collaboratively with the Fall Clinical Grand Rounds Series, invites you to attend a Special Edition of FCVGR:
Join LIVE for a Special Session:
Wednesday, August 12, 2020
17:00 UTC / 18:00 BST / 19:00 CEST
(1 PM EDT / 10 AM PDT for US participants)
COVID-19 and Treatment of Moderate-to-Severe Atopic Dermatitis: The Role of Systemic Agents
Faculty:
Emma Guttman-Yassky, MD, PhD
USA President, International Eczema Council
Sol and Clara Kest Professor and Vice Chair for Research
Department of Dermatology
Director of the Center for Excellence in Eczema
Director of the Laboratory of Inflammatory Skin Diseases
Icahn School of Medicine at
Mount Sinai
New York, NY
Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Many clinicians like yourself remain highly concerned about appropriately managing their Atopic Dermatitis patients during the COVID-19 pandemic. Many of the AD treatment options, and particularly those approved in Europe, are immunosuppressive and pose a risk to patients ie: methotrexate, cyclosporine, steroids, azathioprine and mycophenolate. Therefore, the Fall Clinical Virtual Grand Rounds Series is proud to present a special one hour session devoted to this topic.
Please join us on August 12th and listen to Drs. Lebwohl and Guttman-Yassky outline recommendations on how to appropriately manage these patients today.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Emma Guttman-Yassky, MD, PhD
USA President, International Eczema Council
Sol and Clara Kest Professor and Vice Chair for Research
Department of Dermatology
Director of the Center for Excellence in Eczema
Director of the Laboratory of Inflammatory Skin Diseases
Icahn School of Medicine at
Mount Sinai
New York, NY
Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Many clinicians like yourself remain highly concerned about appropriately managing their Atopic Dermatitis patients during the COVID-19 pandemic. Many of the AD treatment options, and particularly those approved in Europe, are immunosuppressive and pose a risk to patients ie: methotrexate, cyclosporine, steroids, azathioprine and mycophenolate. Therefore, the Fall Clinical Virtual Grand Rounds Series is proud to present a special one hour session devoted to this topic.
Please join us on August 12th and listen to Drs. Lebwohl and Guttman-Yassky outline recommendations on how to appropriately manage these patients today.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
[fc+289]